157 related articles for article (PubMed ID: 14563636)
1. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.
Bellucci R; Wu CJ; Chiaretti S; Weller E; Davies FE; Alyea EP; Dranoff G; Anderson KC; Munshi NC; Ritz J
Blood; 2004 Jan; 103(2):656-63. PubMed ID: 14563636
[TBL] [Abstract][Full Text] [Related]
2. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
[TBL] [Abstract][Full Text] [Related]
3. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
[TBL] [Abstract][Full Text] [Related]
4. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
[TBL] [Abstract][Full Text] [Related]
5. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma.
Orsini E; Alyea EP; Chillemi A; Schlossman R; McLaughlin S; Canning C; Soiffer RJ; Anderson KC; Ritz J
Biol Blood Marrow Transplant; 2000; 6(4):375-86. PubMed ID: 10917573
[TBL] [Abstract][Full Text] [Related]
6. [Allogeneic bone marrow transplantation for refractory multiple myeloma: presence of a graft-versus-myeloma effect].
Nawa Y; Noguchi T; Kojima K; Hara M
Rinsho Ketsueki; 2001 Jun; 42(6):481-7. PubMed ID: 11505527
[TBL] [Abstract][Full Text] [Related]
7. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.
Lokhorst HM; Schattenberg A; Cornelissen JJ; van Oers MH; Fibbe W; Russell I; Donk NW; Verdonck LF
J Clin Oncol; 2000 Aug; 18(16):3031-7. PubMed ID: 10944138
[TBL] [Abstract][Full Text] [Related]
8. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant.
Beitinjaneh AM; Saliba R; Bashir Q; Shah N; Parmar S; Hosing C; Popat U; Anderlini P; Dinh Y; Qureshi S; Rondon G; Champlin RE; Giralt SA; Qazilbash MH
Leuk Lymphoma; 2012 Aug; 53(8):1525-9. PubMed ID: 22242817
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
Du B; Li DP; Xu KL; Pan XY
Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
Bellucci R; Alyea EP; Chiaretti S; Wu CJ; Zorn E; Weller E; Wu B; Canning C; Schlossman R; Munshi NC; Anderson KC; Ritz J
Blood; 2005 May; 105(10):3945-50. PubMed ID: 15692072
[TBL] [Abstract][Full Text] [Related]
11. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.
Lokhorst HM; Schattenberg A; Cornelissen JJ; Thomas LL; Verdonck LF
Blood; 1997 Nov; 90(10):4206-11. PubMed ID: 9354693
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.
Huff CA; Fuchs EJ; Noga SJ; O'Donnell PV; Ambinder RF; Diehl L; Borrello I; Vogelsang GB; Miller CB; Flinn IA; Brodsky RA; Marcellus D; Jones RJ
Biol Blood Marrow Transplant; 2003 May; 9(5):312-9. PubMed ID: 12766881
[TBL] [Abstract][Full Text] [Related]
13. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.
Bellucci R; Alyea EP; Weller E; Chillemi A; Hochberg E; Wu CJ; Canning C; Schlossman R; Soiffer RJ; Anderson KC; Ritz J
Blood; 2002 Jun; 99(12):4610-7. PubMed ID: 12036895
[TBL] [Abstract][Full Text] [Related]
14. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
Collins RH; Shpilberg O; Drobyski WR; Porter DL; Giralt S; Champlin R; Goodman SA; Wolff SN; Hu W; Verfaillie C; List A; Dalton W; Ognoskie N; Chetrit A; Antin JH; Nemunaitis J
J Clin Oncol; 1997 Feb; 15(2):433-44. PubMed ID: 9053463
[TBL] [Abstract][Full Text] [Related]
15. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.
Sehn LH; Alyea EP; Weller E; Canning C; Lee S; Ritz J; Antin JH; Soiffer RJ
J Clin Oncol; 1999 Feb; 17(2):561-8. PubMed ID: 10080600
[TBL] [Abstract][Full Text] [Related]
16. Donor leukocyte infusions for multiple myeloma.
Salama M; Nevill T; Marcellus D; Parker P; Johnson M; Kirk A; Porter D; Giralt S; Levine JE; Drobyski W; Barrett AJ; Horowitz M; Collins RH
Bone Marrow Transplant; 2000 Dec; 26(11):1179-84. PubMed ID: 11149728
[TBL] [Abstract][Full Text] [Related]
17. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
18. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
van de Donk NW; Kröger N; Hegenbart U; Corradini P; San Miguel JF; Goldschmidt H; Perez-Simon JA; Zijlmans M; Raymakers RA; Montefusco V; Ayuk FA; van Oers MH; Nagler A; Verdonck LF; Lokhorst HM
Bone Marrow Transplant; 2006 Jun; 37(12):1135-41. PubMed ID: 16757975
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation for multiple myeloma.
Bellucci R; Ritz J
Rev Clin Exp Hematol; 2002 Sep; 6(3):205-24. PubMed ID: 12616696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]